The IMPAD project aimed to identify immune-related biomarkers in the blood of people with Parkinson's disease. The IMPAD team hopes that blood biomarkers can enable clinicians to easily diagnose, stratify and follow patients based on their presence. The IMPAD project also aimed to identify novel targets for immunomodulation that can be used for treating the disease.
During the project (2021-2023), the IMPAD investigated blood samples from both healthy controls and well-characterized people with Parkinson’s disease to identify changes in the immune system in different subtypes of the disease and at different disease stages. The team used both cellular and protien analyses to determine the condition of the neurons during disease and identify blood biomarkers.
On this page you can can watch a video recorded at the beginning of the IMPAD project. You can also read an article on the output of the project and you can find lists of project participants.
We unite right minds from industry and academia so that they can jointly create need-driven research projects - and pave the way for innovative new treatments in the future. Through competitive funding calls, we fund the best projects ideas. Although companies cannot receive funding, it is free of charge to join.
The 5-year platform is sponsored by the Novo Nordisk Foundation with 180 M DKK from 2024-2028.
You are always welcome to reach out if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although we're spanning five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 121, blg 1521-216.
